| Literature DB >> 33924455 |
Concetta Maria Messina1, Simona Manuguerra1, Rosaria Arena1, Giuseppe Renda1, Giovanna Ficano1, Mariano Randazzo2, Stefano Fricano3, Saloua Sadok4, Andrea Santulli1,2.
Abstract
Non-edible parts of crustaceans could be a rich source of valuable bioactive compounds such as the carotenoid astaxanthin and peptides, which have well-recognized beneficial effects. These compounds are widely used in nutraceuticals and pharmaceuticals, and their market is rapidly growing, suggesting the need to find alternative sources. The aim of this work was to set up a pilot-scale protocol for the reutilization of by-products of processed shrimp, in order to address the utilization of this valuable biomass for nutraceutical and pharmaceuticals application, through the extraction of astaxanthin-enriched oil and antioxidant-rich protein hydrolysates. Astaxanthin (AST) was obtained using "green extraction methods," such as using fish oil and different fatty acid ethyl esters as solvents and through supercritical fluid extraction (SFE), whereas bioactive peptides were obtained by protease hydrolysis. Both astaxanthin and bioactive peptides exhibited bioactive properties in vitro in cellular model systems, such as antioxidant and angiotensin I converting enzyme (ACE) inhibitory activities (IA). The results show higher astaxanthin yields in ethyl esters fatty acids (TFA) extraction and significant enrichment by short-path distillation (SPD) up to 114.80 ± 1.23 µg/mL. Peptide fractions of <3 kDa and 3-5 kDa exhibited greater antioxidant activity while the fraction 5-10 kDa exhibited a better ACE-IA. Lower-molecular-weight bioactive peptides and astaxanthin extracted using supercritical fluids showed protective effects against oxidative damage in 142BR and in 3T3 cell lines. These results suggest that "green" extraction methods allow us to obtain high-quality bioactive compounds from large volumes of shrimp waste for nutraceutical and pharmaceutical applications.Entities:
Keywords: PUFA; SPD; antioxidant activity; astaxanthin; fish oil; protein hydrolysates; proteolytic enzymes; shrimp by-products; supercritical fluid extraction
Year: 2021 PMID: 33924455 PMCID: PMC8070669 DOI: 10.3390/md19040216
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Proximate composition (g/100 g DW a) of P. longirostris by-products (BP).
| g/100 g | |
|---|---|
| Moisture | 3.43 ± 0.16 |
| Ash | 36.40 ± 0.61 |
| Lipid | 4.96 ± 0.17 |
| Protein | 38.47 ± 0.46 |
| Chitin | 16.75 ± 1.06 |
a sample dry weight.
Fatty acid profile (% of total fatty acids) of wet (WBP) and dry (DBP) P. longirostris by-products. EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid.
| WBP | DBP | |
|---|---|---|
| 14:0 | 1.47 ± 0.06 | 0.83 ± 0.08 |
| 16:0 | 17.67 ± 0.20 | 13.10 ± 0.61 |
| 16:1n-7 | 3.40 ± 0.22 | 2.46 ± 0.13 |
| 16:2n-4 | 0.38 ± 0.05 | 0.29 ± 0.03 |
| 16:3n-4 | 0.70 ± 0.06 | 0.67 ± 0.04 |
| 18:0 | 6.61 ± 0.18 | 6.02 ± 0.13 |
| 18:1n-9 | 18.25 ± 1.91 | 22.84 ± 0.55 |
| 18:1n-7 | 4.03 ± 0.18 | 3.81 ± 0.16 |
| 18:2n-6 | 4.00 ± 1.67 | 15.24 ± 0.51 |
| 18:3n-4 | 0.23 ± 0.05 | 0.19 ± 0.03 |
| 18:3n-3 | 0.52 ± 0.04 | 0.36 ± 0.04 |
| 18:4n-3 | 0.29 ± 0.05 | 0.16 ± 0.02 |
| 20:1n-9 | 1.54 ± 0.07 | 1.34 ± 0.04 |
| 20:4n-6 | 4.68 ± 0.39 | 4.32 ± 0.33 |
| 20:4n-3 | 0.38 ± 0.05 | 0.23 ± 0.06 |
| 20:5n-3 (EPA) | 11.97 ± 1.07 | 9.69 ± 0.43 |
| 22:1n-11 | 0.68 ± 0.06 | 0.53 ± 0.04 |
| 22:1n-9 | 0.31 ± 0.08 | 0.26 ± 0.06 |
| 22:5n-3 | 1.26 ± 0.27 | 1.04 ± 0.14 |
| 22:6n-3 (DHA) | 21.66 ± 1.73 | 16.45 ± 0.90 |
| Saturated | 25.74 ± 0.31 | 19.95 ± 0.74 |
| Monounsaturated | 28.21 ± 1.72 | 31.24 ± 0.45 |
| Tot n-3 | 36.08 ± 2.94 | 27.92 ± 1.47 |
| Tot n-6 | 8.67 ± 1.34 | 19.56 ± 0.51 |
| DHA/EPA | 1.81 ± 0.04 | 1.70 ± 0.05 |
Figure 1Degree of hydrolysis (DH%) determined in WBP and DBP during reaction with Protamex®.
Figure 2Sodium dodecyl sulphate poly-acrilamide-electrophoresis (SDS PAGE) of P. longirostris protein hydrolysates (PH) obtained with Protamex® from T0 to T30 min of reaction. Standard molecular weight marker (M).
Figure 31,1-diphenyl-2-picryhydrazyl (DPPH) radical inhibition (%) of peptide fractions (Pep) at different concentrations (1, 2, and 4 mg protein/mL) obtained by hydrolysis with Protamex®. Gallic acid equivalents (GAE 0.01–1 mg/mL) (* p < 0.05) compared to activity of PH.
Figure 4Angiotensin-converting-enzyme inhibition activity (ACE–IA) (expressed in percentage), exerted by peptide fractions obtained by Protamex® and ultrafiltration. Lowercase letters (a–c) indicate significant differences vs. PH (p < 0.05).
Astaxanthin (AST) yields (µg/g on a dry basis) obtained with different solvents—crude viscera oil (CVO), ethyl esters of total fatty acid obtained from CVO (TFA), polyunsaturated fatty acid ethyl esters enriched by short path distillation (SPD) (PUFAE), and exhausted fatty acid ethyl esters (EFA)—and different solvent extraction volume/matrix weight ratios (ER: 0.5; 1.0; 2.0), using WBP and DBP.
| ER | WBP | DBP | ||
|---|---|---|---|---|
| CVO | 0.5 | 80.21 ± 2.0 e | 52.56 ± 0.74 e | * |
| TFA | 86.14 ± 1.88 f | 47.81 ± 3.16 d | * | |
| PUFAE | 31.78 ± 4.19 a | 31.89 ± 1.18 b | - | |
| EFA | 27.17 ± 3.54 a | 19.02 ± 3.74 a | * | |
| CVO | 1.0 | 97.99 ± 1.30 g | 64.22 ± 2.05 g | * |
| TFA | 105.23 ± 3.15 h | 58.41 ± 2.88 f | * | |
| PUFAE | 38.83 ± 6.81 b | 38.96 ± 5.54 c | - | |
| EFA | 33.20 ± 2.30 a,b | 23.23 ± 4.08 a | * | |
| CVO | 2.0 | 149.06 ± 0.82 i | 97.68 ± 1.51 h | * |
| TFA | 160.06 ± 8.91 l | 88.85 ± 7.34 h | * | |
| PUFAE | 59.06 ± 4.06 d | 59.26 ± 3.78 f,g | - | |
| EFA | 50.50 ± 0.91 c | 35.34 ± 1.60 b,c | * |
Different lowercase letters in the same column indicate significant differences (a, b, c… p < 0.05). * in the same row indicates significant differences between wet and dry. Data are reported as mean ± standard deviation.
Figure 5(a) AST concentrations (µg/mL) obtained in the residue via short path distillation (SPD) at different evaporation temperatures. (b) AST concentrations (µg/mL) obtained in the residue via SPD by repeating several steps at the same evaporation temperature (160 °C). Different letters (a,b,c, …) indicate significant differences (p < 0.05).
Figure 6Effect of hydrolyzed fractions on 142RB fibroblast cells exposed to oxidative stress induced by hydrogen peroxide (50 µM). Control–cells maintained in standard culture conditions; HP–hydrogen peroxide treatment; NAC–cells pretreated with the synthetic antioxidant N acetylcysteine. Peptide fractions were obtained by ultrafiltration of BP hydrolysates with Protamex® (Pep). Different letters (a, b, c) indicate significant differences (p < 0.05).
Figure 7Effect of AST extracted using various methods on the viability of 3T3 cells exposed to oxidative stress with hydrogen peroxide (50 µM). HP-hydrogen peroxide treatment; Control-cells maintained in standard culture conditions; CVO-crude viscera oil; TFA-ethyl esters of total fatty acid obtained from CVO; PUFAE-polyunsaturated fatty acid ethyl esters enriched by SPD; EFA-exhausted fatty acid ethyl esters; SFE-supercritical fluid extract. Different letters (a,b) indicate significant difference (p < 0.05).
Operating conditions used for degassing and molecular distillation.
| Degassing | Distillation | |
|---|---|---|
| Flow (htz) | 20 | 5 |
| T (°C) Feed | 40 | 40 |
| T (°C) Condenser | 25 | 60 |
| T (°C) Residue | 60 | 60 |
| T (°C) Evaporator | 80 | 80–240 |
| Vacuum (mbar) | 5 | 2 × 10−3 |